C12N 2740/10022
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2740/10022 (New viral proteins or individual genes, new structural or functional aspects of) appears on 128 US grants and 157 published applications in this corpus.
Search patents in C12N- Granted patents
- 128
- Published applications
- 157
- Assignees
- 121
- Inventors
- 349
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 2 | 0 |
| 1993 | 1 | 0 |
| 1994 | 2 | 0 |
| 1995 | 0 | 0 |
| 1996 | 4 | 0 |
| 1997 | 3 | 0 |
| 1998 | 6 | 0 |
| 1999 | 9 | 0 |
| 2000 | 6 | 0 |
| 2001 | 7 | 0 |
| 2002 | 6 | 7 |
| 2003 | 9 | 11 |
| 2004 | 4 | 13 |
| 2005 | 3 | 7 |
| 2006 | 4 | 2 |
| 2007 | 2 | 6 |
| 2008 | 4 | 13 |
| 2009 | 5 | 7 |
| 2010 | 5 | 9 |
| 2011 | 5 | 5 |
| 2012 | 3 | 4 |
| 2013 | 1 | 1 |
| 2014 | 1 | 1 |
| 2015 | 0 | 3 |
| 2016 | 2 | 1 |
| 2017 | 1 | 1 |
| 2018 | 3 | 1 |
| 2019 | 2 | 8 |
| 2020 | 2 | 7 |
| 2021 | 5 | 6 |
| 2022 | 2 | 12 |
| 2023 | 1 | 7 |
| 2024 | 6 | 13 |
| 2025 | 7 | 7 |
| 2026 | 2 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Virus-like particle16 Jun 2026US 12,655,388 B2Autolus Limited
- Arc-based capsids and uses thereof5 May 2026US 12,617,822 B2Aera Therapeutics, Inc.
- Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells2 Sep 2025US 12,404,525 B2President and Fellows of Harvard College
- Nucleic acids encoding human endogenous retrovirus K (HERV-k) envelope proteins containing modified immunosuppressive domains (ISD) and uses thereof19 Aug 2025US 12,390,522 B2Inprother Aps
- Fusosome compositions and uses thereof5 Aug 2025US 12,378,578 B2Flagship Pioneering Innovations V, Inc.
- Use of rtl8-deficient cells to produce biocompatible, peg10-derived virus-like particles (vlp)30 Jul 2026US 2026/0218135 A1The Regents of the University of Colorado, a body corporate
- Gene therapy30 Apr 2026US 2026/0115317 A1
- Nucleic acids encoding human endogenous retrovirus k (herv-k) envelope proteins containing modified immunosuppressive domains (isd) and uses thereof19 Mar 2026US 2026/0077031 A1Inprother Aps
- Uptake mechanism of essential lysophospholipids into the brain and inhibition by endogenous-retroviral envelope protein5 Mar 2026US 2026/0062455 A1
- Herv-k (hml-2) env analog fusion proteins for antigen specific immunotherapy and methods of use5 Feb 2026US 2026/0035414 A1Twilight Bioscience, Inc.
Most cited
By later US patents
- Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus153US 4,777,127 ALabsystems Oy · 1988
- Endogenous retroviruses up-regulated in prostate cancer68US 7,776,523 B2Novartis Vaccines and Diagnostics, Inc. · 2010
- Stable DNA constructs for expression of .alpha.-1 antitrypsin49US 4,931,373 AZymoGenetics, Inc. · 1990
- Antisense viruses and antisense-ribozyme viruses28US 6,107,062 AInpax, Inc. · 2000
- Packaging cell22US 6,995,009 B1Chugai Seiyaku Kabushiki Kaisha · 2006